CBI Dimer Antibody-Drug Conjugate Linker Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in optimizing antibody selection, linker design, and drug conjugation stability, which affects their therapeutic efficacy against cancer cells.
Innovation Solution
The development of antibody-drug conjugates using 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moieties linked to antibodies through specific linker units, enabling targeted delivery and release of cytotoxic agents within cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CBI dimer drug moieties are conjugated to antibodies through linker units, then the therapeutic efficacy and targeting capability are improved, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The ADC is divided into distinct functional segments: the antibody portion for targeting, the linker unit for connection and stability, and the CBI dimer drug moiety for cytotoxic activity. This segmentation allows each component to be optimized independently while maintaining overall therapeutic efficacy.
Solution Approach 2:
The invention creates a composite molecular structure combining biological (antibody) and chemical (CBI dimer drug moiety via linker) components. This composite approach integrates the specificity of antibodies with the potency of CBI dimers, achieving enhanced therapeutic effect while managing structural complexity through systematic design.
2Reliability
If CBI dimer drug moieties are conjugated to antibodies, then the anti-tumor activity is enhanced, but the difficulty of detecting and measuring increases
Solution Approach 1:
The linker unit is designed with specific local chemical properties (reactive groups, spacer lengths, stability characteristics) that facilitate both the conjugation process and subsequent characterization. The distinct chemical environment at the conjugation site enables targeted analytical approaches for detecting and measuring the ADC structure.
3Stability of the object's composition
If specific linker units are used for conjugation, then the stability and targeted delivery are improved, but the ease of manufacture decreases
Solution Approach 1:
The linker unit serves as an intermediary component between the antibody and CBI dimer drug moiety. It provides a stable connection while incorporating reactive groups that facilitate controlled conjugation under mild conditions, balancing stability with manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the therapeutic efficacy of ADCs by improving the targeting and internalization of cytotoxic drugs within tumor cells, leading to increased anti-tumor activity and potential diagnostic applications.
Implementation Method 1
The 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indole (amino CBI) class of DNA minor groove alkylators are potent cytotoxins
Implementation Method 2
antibody selection, linker design and stability, cytotoxic drug potency and mode of drug and linker conjugation to the antibody
Implementation Method 3
targeting potent cytotoxic drugs to antigen-expressing tumor cells, internalization, and release of drug
Data Source
AI summary
The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.